Mountain Capital Investment Advisors Inc raised its position in shares of Pfizer Inc. (NYSE:PFE) by 34.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,628 shares of the biopharmaceutical company’s stock after acquiring an additional 4,215 shares during the period. Pfizer makes up about 0.5% of Mountain Capital Investment Advisors Inc’s investment portfolio, making the stock its 14th largest position. Mountain Capital Investment Advisors Inc’s holdings in Pfizer were worth $594,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of PFE. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer during the second quarter valued at about $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer during the second quarter valued at about $103,000. D. Scott Neal Inc. lifted its position in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at about $120,000. Finally, Lipe & Dalton lifted its position in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 69.87% of the company’s stock.
PFE has been the subject of several analyst reports. BMO Capital Markets set a $37.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 10th. Barclays set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $39.25.
In other news, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down $1.94 during trading on Monday, reaching $34.67. 39,351,947 shares of the company were exchanged, compared to its average volume of 20,260,000. Pfizer Inc. has a 1 year low of $31.67 and a 1 year high of $39.43. The firm has a market cap of $206,660.00, a PE ratio of 9.85, a P/E/G ratio of 2.20 and a beta of 0.94. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The firm had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter last year, the company earned $0.47 EPS. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. sell-side analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.92%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is presently 38.64%.
Pfizer announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/05/pfizer-inc-pfe-stake-raised-by-mountain-capital-investment-advisors-inc.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.